IQVIA Holdings (IQV) Stock Price
IQVIA Holdings Price
Revenue has compounded at 9.0% per year over the past 17 years to 16.31 B USD. Earnings per share have grown at 21.2% per year over the last 17 years. IQVIA Holdings's net margin stands at 8.3%, up from 7.0% several years earlier. Analysts set a median price target of 240.00 USD, implying 8.1% below the current price. Of 28 analysts, 23 rate the stock a buy — an overall Buy consensus.
IQVIA Holdings stock price
IQVIA Holdings business model & stock analysis
Frequently asked questions about IQVIA Holdings
IQVIA Holdings Inc is primarily active in the healthcare and pharmaceutical industries. With its comprehensive range of services and solutions, IQVIA plays a crucial role in supporting the advancement of healthcare worldwide. As a leading provider of integrated information and technology-enabled solutions, IQVIA assists pharmaceutical companies, healthcare providers, and researchers in optimizing their operations and making informed decisions. With its vast expertise and global presence, IQVIA continues to drive innovation, improve patient outcomes, and contribute to the overall growth and development of the healthcare industry.
The business model of IQVIA Holdings Inc is focused on providing advanced analytics, technology solutions, and contract research services to the life sciences industry. IQVIA offers a wide range of services, including clinical trial support, real-world evidence solutions, commercial effectiveness, and healthcare data management. Through leveraging its vast network of healthcare professionals and extensive data resources, IQVIA helps pharmaceutical, biotech, and medical device companies navigate the complex healthcare landscape, drive innovation, and improve patient outcomes.
The main competitors of IQVIA Holdings Inc in the market include companies such as LabCorp, PRA Health Sciences, ICON PLC, and Syneos Health.
IQVIA Holdings Inc, formerly known as Quintiles IMS Holdings Inc, is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company was formed in 2016 through the merger of Quintiles Transnational Holdings Inc and IMS Health Holdings Inc. With a history dating back to 1982, IQVIA has been at the forefront of transforming the way pharmaceutical, biotechnology, and healthcare companies operate. Today, IQVIA leverages its extensive data, domain expertise, and innovative technologies to improve clinical trial outcomes, enhance real-world evidence solutions, and drive healthcare intelligence for its clients.
IQVIA Holdings Inc has achieved several significant milestones in its history. One notable achievement is the merger between IMS Health and Quintiles Transnational in 2016, which led to the formation of IQVIA. This merger created a leading global provider of advanced analytics, technology solutions, and contract research services to the healthcare industry. Another milestone is the company's consistent focus on innovation and cutting-edge research. IQVIA has pioneered groundbreaking solutions in areas such as real-world evidence, patient centricity, and digital health. Additionally, IQVIA has expanded its global footprint and established a strong presence in key markets worldwide. These achievements have solidified IQVIA Holdings Inc as a frontrunner in the healthcare and life sciences industry.
IQVIA Holdings Inc is primarily present in various countries and regions across the globe. As a leading provider of advanced analytics, technology solutions, and clinical research services, IQVIA operates in more than 100 countries worldwide. With a strong presence in North America, Europe, Asia-Pacific, and the Middle East, IQVIA caters to the needs of pharmaceutical, biotechnology, and healthcare companies across these regions. The company's extensive global reach positions it well to support and collaborate with clients on a global scale.
IQVIA Holdings Inc is known for its strong values and corporate philosophy. The company emphasizes innovation, integrity, and collaboration. With a commitment to advancing healthcare, IQVIA strives to improve patient outcomes and support the life sciences industry. By combining cutting-edge technology, data analytics, and deep industry expertise, IQVIA delivers actionable insights and solutions to its clients. The company's dedication to ethical practices, global impact, and teamwork sets it apart in the market. IQVIA Holdings Inc continuously works towards transforming healthcare through its core values and corporate philosophy.
Analysts currently set an average price target of 238.22 USD for the IQVIA Holdings stock (median: 240.00 USD), implying -9.1 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the IQVIA Holdings stock: 23 recommend buying, 5 holding and 0 selling. For 2026, analysts expect IQVIA Holdings to generate revenue of 17.42 B USD and earnings per share of 13.09 USD.
Converted at the current exchange rate, the IQVIA Holdings share trades at 233.47 EUR (261.04 USD).
The IQVIA Holdings share (IQV) is listed on 9 stock exchanges, including: NYSE (IQV), London (0JDM.L), SIX (Zürich) (QTS.SW), XETRA (QTS.DE), Frankfurt (QTS.F), München (QTS.MU), Düsseldorf (QTS.DU), Wien (IQVH.VI).
IQVIA Holdings Inc. is a global leader in the healthcare industry. It combines biomedical insights in innovative ways to improve global health. IQVIA offers various divisions, including research and analysis solutions, technology platforms, clinical development, and commercial support. Its mission is to enhance patient care while reducing healthcare costs. The company provides a wide range of products and services tailored to customer needs, with the overarching goal of improving patient outcomes worldwide.
The expected revenue of IQVIA Holdings is 17.42 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of IQVIA Holdings is 2.25 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IQVIA Holdings is currently 19.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IQVIA Holdings stock.
The price-to-sales ratio (P/S) of IQVIA Holdings is currently 2.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IQVIA Holdings stock.
The Eulerpool Quality Score for IQVIA Holdings is 6/10.
The ISIN of IQVIA Holdings is US46266C1053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IQVIA Holdings is A2JSPM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IQVIA Holdings is IQV. The ticker symbol is used to trade IQVIA Holdings shares on the stock exchange.
IQVIA Holdings stock
IQVIA Holdings Peer Group
IQVIA Holdings Ticker
IQVIA Holdings FIGI
All fundamentals and in-depth analysis of IQVIA Holdings
Our stock analysis for IQVIA Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IQVIA Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.